{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T02:12:04Z","timestamp":1770603124984,"version":"3.49.0"},"reference-count":49,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The most common complication in hemophilia A (HA) treatment, affecting 25% to 30% of patients with severe HA, is the development of alloimmune inhibitors that foreclose the ability of infused factor VIII (FVIII) to participate in coagulation. Inhibitors confer significant pathology on affected individuals and present major complexities in their management. Inhibitors are more common in African American patients, and it has been hypothesized that this is a consequence of haplotype (H)-treatment product mismatch. F8 haplotypes H1 to H5 are defined by nonsynonymous single-nucleotide polymorphisms encoding sequence variations at FVIII residues 1241, 2238, and 484. Haplotypes H2 to H5 are more prevalent in individuals with Black African ancestry, whereas 80% to 90% of the White population has the H1 haplotype. This study used an established multiplex fluorescence immunoassay to determine anti-FVIII antibody titers in plasma from 394 individuals with HA (188 Black, 206 White), measuring their binding to recombinant full-length H1 and H2 and B-domain\u2013deleted (BDD) H1\/H2, H3\/H5, and H4 FVIII proteins. Inhibitor titers were determined using a chromogenic assay and linear B-cell epitopes characterized using peptide microarrays. FVIII-reactive antibodies were readily detected in most individuals with HA, with higher titers in those with a current inhibitor, as expected. Neither total nor inhibitory antibody titers correlated with F8 haplotype mismatches, and\u00a0peptides with D1241E and M2238V polymorphisms did not comprise linear B-cell epitopes. Interestingly, compared with the full-length FVIII products, the BDD-FVIII proteins were markedly more reactive with plasma antibodies. The stronger immunoreactivity of BDD-FVIII suggests that B-domain removal might expose novel B-cell epitopes, perhaps through conformational rearrangements of FVIII domains.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021004909","type":"journal-article","created":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T18:07:24Z","timestamp":1670004444000},"page":"4983-4998","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Anti-FVIII antibodies in Black and White hemophilia A subjects: do <i>F8<\/i> haplotypes play a role?"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6837-6133","authenticated-orcid":false,"given":"Kathleen P.","family":"Pratt","sequence":"first","affiliation":[{"name":"1Uniformed Services University of the Health Sciences, Bethesda, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devi","family":"Gunasekera","sequence":"additional","affiliation":[{"name":"1Uniformed Services University of the Health Sciences, Bethesda, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pooja","family":"Vir","sequence":"additional","affiliation":[{"name":"1Uniformed Services University of the Health Sciences, Bethesda, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyuan","family":"Tan","sequence":"additional","affiliation":[{"name":"2Independent Consultant, Cambridge, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3310-328X","authenticated-orcid":false,"given":"Glenn F.","family":"Pierce","sequence":"additional","affiliation":[{"name":"3Independent Consultant, La Jolla, CA"},{"name":"4World Federation of Hemophilia, Montreal, QC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cara","family":"Olsen","sequence":"additional","affiliation":[{"name":"1Uniformed Services University of the Health Sciences, Bethesda, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saulius","family":"Butenas","sequence":"additional","affiliation":[{"name":"5College of Medicine, University of Vermont, Burlington, VT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth G.","family":"Mann","sequence":"additional","affiliation":[{"name":"5College of Medicine, University of Vermont, Burlington, VT"},{"name":"6Haematologic Technologies, Inc, Colchester, VT"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2023,8,28]]},"reference":[{"issue":"1","key":"2023091115342586700_bib1","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1046\/j.1365-2516.1998.0146c.x","article-title":"Inhibitors occur more frequently in African-American and Latino haemophiliacs","volume":"4","author":"Aledort","year":"1998","journal-title":"Haemophilia"},{"issue":"3","key":"2023091115342586700_bib2","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1365-2516.2011.02700.x","article-title":"F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race\/ethnicity","volume":"18","author":"Miller","year":"2012","journal-title":"Haemophilia"},{"issue":"7","key":"2023091115342586700_bib3","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1182\/blood-2014-09-599365","article-title":"Factor VIII gene variants and inhibitor risk in African American hemophilia A patients","volume":"126","author":"Gunasekera","year":"2015","journal-title":"Blood"},{"issue":"16","key":"2023091115342586700_bib4","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1056\/NEJMoa075760","article-title":"Inhibitors of factor VIII in black patients with hemophilia","volume":"360","author":"Viel","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2023091115342586700_bib5","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1182\/blood-2006-06-026104","article-title":"A\u00a0sequence variation scan of the coagulation factor VIII (FVIII) structural gene and associations with plasma FVIII activity levels","volume":"109","author":"Viel","year":"2007","journal-title":"Blood"},{"issue":"4","key":"2023091115342586700_bib6","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jtha.2022.12.017","article-title":"Race, ethnicity, F8 variants, and inhibitor risk: analysis of the \u201cMy Life Our Future\u201d hemophilia A database","volume":"21","author":"Ahmed","year":"2023","journal-title":"J Thromb Haemost."},{"issue":"1","key":"2023091115342586700_bib7","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/hae.12004","article-title":"F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) combined cohort","volume":"19","author":"Schwarz","year":"2013","journal-title":"Haemophilia"},{"issue":"5","key":"2023091115342586700_bib8","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/hae.12436","article-title":"Genetic factors influencing inhibitor development in a cohort of South African haemophilia A patients","volume":"20","author":"Lochan","year":"2014","journal-title":"Haemophilia"},{"issue":"11","key":"2023091115342586700_bib9","doi-asserted-by":"crossref","first-page":"6665","DOI":"10.4049\/jimmunol.166.11.6665","article-title":"Tetramer-guided epitope mapping: rapid identification and characterization of immunodominant CD4+ T cell epitopes from complex antigens","volume":"166","author":"Novak","year":"2001","journal-title":"J\u00a0Immunol"},{"issue":"11","key":"2023091115342586700_bib10","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1182\/blood-2008-08-174987","article-title":"Quantitation of anti-factor VIII antibodies in human plasma","volume":"113","author":"Krudysz-Amblo","year":"2009","journal-title":"Blood"},{"issue":"4","key":"2023091115342586700_bib11","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/hae.12127","article-title":"Product-dependent anti-factor VIII antibodies","volume":"19","author":"Butenas","year":"2013","journal-title":"Haemophilia"},{"issue":"4","key":"2023091115342586700_bib12","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/j.1365-2516.2010.02468.x","article-title":"Alloantibodies to factor VIII in haemophilia","volume":"17","author":"Zakarija","year":"2011","journal-title":"Haemophilia"},{"issue":"6","key":"2023091115342586700_bib13","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2012-07-444877","article-title":"Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients","volume":"121","author":"Whelan","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2023091115342586700_bib14","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1365-2141.2008.07232.x","article-title":"IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with hemophilia A","volume":"142","author":"van Helden","year":"2008","journal-title":"Br J Haematol"},{"issue":"1","key":"2023091115342586700_bib15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/jth.12768","article-title":"Characterization of the anti-factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence-based immunoassay","volume":"13","author":"Boylan","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"issue":"7","key":"2023091115342586700_bib16","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1182\/blood-2014-09-598268","article-title":"Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans","volume":"125","author":"Hofbauer","year":"2015","journal-title":"Blood"},{"issue":"12","key":"2023091115342586700_bib17","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1182\/blood-2011-09-379453","article-title":"F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis","volume":"119","author":"Gouw","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2023091115342586700_bib18","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1111\/j.1365-2516.2011.02739.x","article-title":"Increased prevalence of inhibitors in Hispanic patients with severe haemophilia A enrolled in the Universal Data Collection database","volume":"18","author":"Carpenter","year":"2012","journal-title":"Haemophilia"},{"issue":"8","key":"2023091115342586700_bib19","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1055\/s-0029-1245105","article-title":"The multifactorial etiology of inhibitor development in hemophilia: genetics and environment","volume":"35","author":"Gouw","year":"2009","journal-title":"Semin Thromb Hemost"},{"key":"2023091115342586700_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2020.01219","article-title":"Hemophilia A inhibitor subjects show unique PBMC gene expression profiles that include up-regulated innate immune modulators","volume":"11","author":"Karim","year":"2020","journal-title":"Front Immunol"},{"issue":"9","key":"2023091115342586700_bib21","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.1073\/pnas.89.9.3795","article-title":"Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals","volume":"89","author":"Algiman","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"2023091115342586700_bib22","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1111\/jth.14204","article-title":"In-depth comparison of N-glycosylation of human plasma-derived factor VIII and different recombinant products: from structure to clinical implications","volume":"16","author":"Canis","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2023091115342586700_bib23","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1055\/s-0037-1615873","article-title":"CD4+ T cell response to factor VIII in hemophilia A, acquired hemophilia, and healthy subjects","volume":"82","author":"Reding","year":"1999","journal-title":"Thromb Haemost"},{"issue":"21","key":"2023091115342586700_bib24","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1182\/bloodadvances.2017008706","article-title":"CD4 T cells specific for factor VIII are present at high frequency in healthy donors and comprise naive and memory cells","volume":"1","author":"Meunier","year":"2017","journal-title":"Blood Adv"},{"issue":"10","key":"2023091115342586700_bib25","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1046\/j.1538-7836.2003.00366.x","article-title":"Recognition of coagulation factor VIII by CD4+ T cells of healthy humans","volume":"1","author":"Hu","year":"2003","journal-title":"J\u00a0Thromb Haemost"},{"issue":"3","key":"2023091115342586700_bib26","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1538-7836.2007.02336.x","article-title":"Depletion of CD4+\/CD25high regulatory T cells may enhance or uncover factor VIII-specific T-cell responses in healthy individuals","volume":"5","author":"Kamate","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"issue":"3","key":"2023091115342586700_bib27","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1182\/bloodadvances.2021005745","article-title":"Nonneutralizing FVIII-specific antibody signatures in patients with hemophilia A and in healthy donors","volume":"6","author":"Schweiger","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"2023091115342586700_bib28","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1111\/hae.14202","article-title":"Evaluation of anti-factor VIII antibody levels in patients with haemophilia A receiving immune tolerance induction therapy or bypassing agents","volume":"27","author":"Boylan","year":"2021","journal-title":"Haemophilia"},{"issue":"11","key":"2023091115342586700_bib29","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.3324\/haematol.2018.188219","article-title":"N-linked glycosylation modulates the immunogenicity of recombinant human factor VIII in hemophilia A mice","volume":"103","author":"Lai","year":"2018","journal-title":"Haematologica"},{"issue":"11","key":"2023091115342586700_bib30","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1111\/j.1538-7836.2011.04472.x","article-title":"Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-analysis of prospective clinical studies","volume":"9","author":"Aledort","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"issue":"11","key":"2023091115342586700_bib31","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1111\/j.1538-7836.2011.04496.x","article-title":"Best evidence on B-domain deletion and the immunogenicity of recombinant factor VIII","volume":"9","author":"Aledort","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"issue":"2","key":"2023091115342586700_bib32","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/hae.12563","article-title":"The incidence of factor VIII inhibitors in severe haemophilia A following a major switch from full-length to B-domain-deleted factor VIII: a prospective cohort comparison","volume":"21","author":"Hay","year":"2015","journal-title":"Haemophilia"},{"issue":"6","key":"2023091115342586700_bib33","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/hae.13551","article-title":"The immunogenicity of ReFacto AF (moroctocog alfa AF-CC) in previously untreated patients with haemophilia A in the United Kingdom","volume":"24","author":"Mathias","year":"2018","journal-title":"Haemophilia"},{"issue":"4","key":"2023091115342586700_bib34","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/hae.13466","article-title":"Clinical experience with moroctocog alfa (AF-CC) in younger paediatric patients with severe haemophilia A: two open-label studies","volume":"24","author":"Rusen","year":"2018","journal-title":"Haemophilia"},{"issue":"3","key":"2023091115342586700_bib35","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1056\/NEJMoa1208024","article-title":"Factor VIII products and inhibitor development in severe hemophilia A","volume":"368","author":"Gouw","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2023091115342586700_bib36","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1056\/NEJMoa1208024","article-title":"Factor VIII products and inhibitor development in severe hemophilia A","volume":"368","author":"van den Berg","year":"2013","journal-title":"N Engl J Med"},{"issue":"23","key":"2023091115342586700_bib37","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1182\/blood-2014-07-580498","article-title":"Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011","volume":"124","author":"Collins","year":"2014","journal-title":"Blood"},{"issue":"23","key":"2023091115342586700_bib38","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2014-07-586347","article-title":"Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A","volume":"124","author":"Calvez","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2023091115342586700_bib39","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3324\/haematol.2017.174706","article-title":"Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A","volume":"103","author":"Calvez","year":"2018","journal-title":"Haematologica"},{"issue":"6","key":"2023091115342586700_bib40","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/jth.14124","article-title":"Factor VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: a systematic review","volume":"16","author":"Hassan","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"issue":"11","key":"2023091115342586700_bib41","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1111\/j.1538-7836.2011.04480.x","article-title":"Concentrate-related inhibitor risk: is a difference always real?","volume":"9","author":"Iorio","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"issue":"10","key":"2023091115342586700_bib42","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/2040620717721458","article-title":"Current and emerging factor VIII replacement products for hemophilia A","volume":"8","author":"Cafuir","year":"2017","journal-title":"Ther Adv Hematol"},{"issue":"21","key":"2023091115342586700_bib43","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1056\/NEJMoa1516437","article-title":"A\u00a0randomized trial of factor VIII and neutralizing antibodies in hemophilia A","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"2023091115342586700_bib44","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1182\/blood-2007-06-096842","article-title":"Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation","volume":"110","author":"Meeks","year":"2007","journal-title":"Blood"},{"issue":"5","key":"2023091115342586700_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0061120","article-title":"Phenotypes of allo- and autoimmune antibody responses to FVIII characterized by surface plasmon resonance","volume":"8","author":"Lewis","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"2023091115342586700_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0116577","article-title":"Six amino acid residues in a 1200 A2 interface mediate binding of factor VIII to an IgG4kappa inhibitory antibody","volume":"10","author":"Lin","year":"2015","journal-title":"PLoS One"},{"issue":"17","key":"2023091115342586700_bib47","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1182\/blood-2013-09-527275","article-title":"High-resolution mapping of epitopes on the C2 domain of factor VIII by analysis of point mutants using surface plasmon resonance","volume":"123","author":"Nguyen","year":"2014","journal-title":"Blood"},{"key":"2023091115342586700_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2020.00563","article-title":"Prevalence and incidence of non-neutralizing antibodies in congenital hemophilia A- a systematic review and meta-analysis","volume":"11","author":"Abdi","year":"2020","journal-title":"Front Immunol"},{"issue":"4","key":"2023091115342586700_bib49","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/ajh.2830420408","article-title":"Loss of high-responder inhibitors in patients with severe hemophilia A and human immunodeficiency virus type 1 infection: a report from the Multi-Center Hemophilia Cohort Study","volume":"42","author":"Bray","year":"1993","journal-title":"Am J Hematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/17\/4983\/2076998\/blooda_adv-2021-004909-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/17\/4983\/2076998\/blooda_adv-2021-004909-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T15:36:00Z","timestamp":1694446560000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/17\/4983\/493387\/Anti-FVIII-antibodies-in-Black-and-White"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,28]]},"references-count":49,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2023,9,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021004909","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,28]]}}}